國藥現代(600420.SH):青黴素類、大環內酯類原料藥市場需求依然比較旺盛
格隆匯7月16日丨國藥現代(600420.SH)近日在接待機構投資者調研時表示,首先,二季度公司業務發展基本延續了一季度的經營形勢。青黴素類、大環內酯類原料藥市場需求依然比較旺盛。公司充分利用產業鏈優勢,積極把握市場機遇,調整產品結構,提高了高毛利產品的生產銷售佔比。
其次,公司持續強化預算管理,嚴格費用管控,期間費用特別是銷售費用同比下降明顯。
再次,公司持續開展提質增效專項工作,通過改進工藝技術、強化一體化管理、規模化生產等方式,加強成本管控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.